Cambridge Investment Research Advisors
IBIO icon

Cambridge Investment Research Advisors’s iBio IBIO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30
Closed -$16K – 3223
2021
Q3 		$16K Buy
+30
New +$18.7K ﹤0.01% 3065
2021
Q2 		– Sell
-23
Closed -$17K – 3134
2021
Q1 		$17K Buy
+23
New +$20K ﹤0.01% 2848

Other funds holding IBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cambridge Investment Research Advisors's IBIO Position: Q4 2021 in Review

Cambridge Investment Research Advisors sold out of iBio (IBIO) in Q4 2021, closing a stake of 30 shares — an estimated $16K sold.

Cambridge Investment Research Advisors first reported a position in IBIO in Q1 2021 and held it in 2 quarters. The position peaked at $17K in Q1 2021. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

  • Cambridge Investment Research Advisors reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 30 iBio shares in Q4 2021, an estimated $16K.
  • Cambridge Investment Research Advisors first reported a position in iBio in Q1 2021 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's iBio position peaked at $17K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.